Serum GDF 15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain , but Not to Disease Progression in Adult m . 3243 A > G Carriers
暂无分享,去创建一个
D. Vriens | J. Timmermans | J. Smeitink | M. Janssen | L. Kapusta | G. Weijers | F. Sweep | S. Koene | P. Laat | D. V. Tienoven
[1] M. Cerqueira,et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.
[2] A. Domínguez-Rodríguez,et al. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. , 2014, The American journal of cardiology.
[3] S. Yatsuga,et al. Growth Differentiation Factor 15 and Fibroblast Growth Factor 21: Novel Biomarkers for Mitochondrial Diseases , 2014 .
[4] D. Vriens,et al. Serum FGF21 levels in adult m.3243A>G carriers , 2014, Neurology.
[5] D. Zhu,et al. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Mavinkurve-Groothuis,et al. Early myocardial deformation abnormalities in breast cancer survivors , 2014, Breast Cancer Research and Treatment.
[7] Y. Izumiya,et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. , 2014, The Canadian journal of cardiology.
[8] F. Amant,et al. Growth Differentiation Factor-15 as Biomarker in Uterine Sarcomas , 2014, International Journal of Gynecologic Cancer.
[9] M. G. St. John Sutton,et al. Longitudinal Strain in Friedreich Ataxia: A Potential Marker for Early Left Ventricular Dysfunction , 2013, Echocardiography.
[10] L. de Meirleir,et al. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies , 2014, BMC Genomics.
[11] R. Vasan,et al. Biomarkers of cardiovascular stress and incident chronic kidney disease. , 2013, Clinical chemistry.
[12] V. Mootha,et al. New treatments for mitochondrial disease—no time to drop our standards , 2013, Nature Reviews Neurology.
[13] K. Wollert,et al. Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome , 2013, Critical Care.
[14] Robert W. Taylor,et al. Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers† , 2012, European heart journal cardiovascular Imaging.
[15] Andrew D. Johnson,et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. , 2012, Clinical chemistry.
[16] R. Goldschmeding,et al. Circulating growth differentiation factor‐15 correlates with myocardial fibrosis in patients with non‐ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support , 2012, European journal of heart failure.
[17] Robert W. Taylor,et al. Cardiomyopathy is common in patients with the mitochondrial DNA m.3243A>G mutation and correlates with mutation load , 2012, Neuromuscular Disorders.
[18] R. Rodenburg,et al. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation , 2012, Journal of Inherited Metabolic Disease.
[19] F. Marín,et al. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. , 2012, European journal of internal medicine.
[20] J. Carrero,et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] W. Gao,et al. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[22] E. Bertini,et al. Renal involvement in mitochondrial cytopathies , 2011, Pediatric Nephrology.
[23] R. Mayeux. Biomarkers: Potential uses and limitations , 2004, NeuroRX.
[24] A. Suomalainen. Biomarkers for mitochondrial respiratory chain disorders , 2011, Journal of Inherited Metabolic Disease.
[25] H. Kim,et al. Initial Experiences with Proton MR Spectroscopy in Treatment Monitoring of Mitochondrial Encephalopathy , 2010, Yonsei medical journal.
[26] D. Turnbull,et al. Mitochondrial disease in adults: A scale to monitor progression and treatment , 2006, Neurology.
[27] M. Akizuki,et al. Renal complications in a patient with A-to-G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. , 2002, Internal medicine.
[28] W. D. Fairlie,et al. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. , 2000, The Journal of clinical endocrinology and metabolism.